VEGFR2/CD309 Protein (Fc Tag)

Produktnummer ABIN7321053

Produktdetails

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Ratte

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses VEGFR2/CD309 Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Recombinant Rat VEGFR2/CD309/KDR Protein (Fc Tag)(Active)

Sequenz: Met1-Glu760

Produktmerkmale: A DNA sequence encoding the rat KDR (AAH87029.1) (Met1-Glu760) was expressed with the Fc region of human IgG1 at the C-terminus.

Reinheit: > 95 % as determined by SDS-PAGE

Endotoxin-Niveau: < 1.0 EU per μg of the protein as determined by the LAL method

Biological Activity Comment: Immobilized mouse VEGF164 at 10 μg/ml (100 μl/well) can bind rat KDR-Fc, The EC50 of rat KDR-Fc is 0.07-0.15 μg/ml.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Antigendetails

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: VEGFR2/CD309/KDR (VEGFR2 Produkte)

Hintergrund:

Background: VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Synonym: Vegfr-2;KDR;Flk-1

Molekulargewicht: 110 kDa

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling